GeneDx’s (WGS) “Buy” Rating Reiterated at BTIG Research

BTIG Research restated their buy rating on shares of GeneDx (NASDAQ:WGS – Free Report) in a research report report published on Wednesday,Benzinga reports. They currently have a $85.00 target price on the stock.

Several other research firms have also commented on WGS. Weiss Ratings reissued a “sell (d)” rating on shares of GeneDx in a research note on Monday, November 2nd. Zacks Research upgraded shares of GeneDx from a “hold” rating to a “strong-buy” rating in a report on Monday, November 16th. Wall Street Zen upgraded shares of GeneDx from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Canaccord Genuity Group lifted their price target on shares of GeneDx from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Finally, Guggenheim upped their price target on GeneDx from $74.00 to $83.00 and gave the company a “buy” rating in a report on Thursday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $90.14.

View Our Latest Stock Analysis on WGS

GeneDx Price Performance

Shares of GeneDx stock opened at $45.46 on Wednesday. The company has a current ratio of 4.16, a quick ratio of 3.85 and a debt-to-equity ratio of 0.60. The company’s 50-day moving average price is $70.18 and its two-hundred day moving average price is $69.00. GeneDx has a 52 week low of $32.21 and a 52 week high of $170.87. The stock has a market cap of $1.36 billion, a PE ratio of -12.03 and a beta of 2.00.

GeneDx (NASDAQ:WGS – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.21. The company had revenue of $123.10 million during the quarter, compared to analyst estimates of $122.93 million. GeneDx had a negative net margin of 24.10% and a positive return on equity of 1.98%. During the same quarter last year, the firm posted ($0.27) EPS. As a group, sell-side analysts anticipate that GeneDx will post -0.37 EPS for the current fiscal year.

Insider Transactions at GeneDx

In related news, CEO Katherine Stueland sold 10,501 shares of GeneDx stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $97.61, for a total value of $1,025,002.61. Following the transaction, the chief executive officer owned 115,476 shares of the company’s stock, valued at approximately $11,271,612.36. This trade represents a 8.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Kevin Feeley sold 3,728 shares of the business’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $97.61, for a total value of $363,890.08. Following the sale, the chief financial officer owned 44,945 shares in the company, valued at approximately $4,387,081.45. The trade was a 7.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 19,206 shares of company stock worth $1,808,056 in the last three months. 25.17% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Cim LLC boosted its position in shares of GeneDx by 5.4% in the third quarter. Cim LLC now owns 5,225 shares of the company’s stock worth $378,000 after buying an additional 270 shares during the period. Swiss National Bank grew its holdings in shares of GeneDx by 1.0% during the first quarter. Swiss National Bank now owns 40,000 shares of the company’s stock valued at $2,569,000 after buying an additional 400 shares in the last quarter. Fifth Third Bancorp purchased a new position in shares of GeneDx during the first quarter valued at $31,000. Keebeck Wealth Management grew its holdings in shares of GeneDx by 13.5% during the first quarter. Keebeck Wealth Management now owns 4,310 shares of the company’s stock valued at $277,000 after buying an additional 513 shares in the last quarter. Finally, Cetera Investment Advisers raised its position in GeneDx by 16.6% during the first quarter. Cetera Investment Advisers now owns 3,616 shares of the company’s stock valued at $232,000 after buying an additional 516 shares during the period. 61.72% of the stock is owned by hedge funds and other institutional investors.

GeneDx Company Profile

(Get Free Report)

GeneDx is a genomic testing company focused on helping clinicians diagnose rare and inherited conditions. Its services include whole exome and whole genome sequencing, along with other genetic tests and clinical interpretation of results. The company’s testing is used by healthcare providers to support diagnosis and care decisions, particularly for patients with suspected rare genetic disorders. GeneDx also offers testing related to hereditary cancer risk. Founded in 2000 by researchers with experience at the National Institutes of Health, GeneDx has developed its business around applying genomic information in clinical care.

Further Reading

Analyst Recommendations for GeneDx (NASDAQ:WGS)

Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.